期刊文献+

观察胃肠间质瘤患者实施个性化治疗方案的临床效果 被引量:1

Clinical Effect of Individualized Treatment for Gastrointestinal Stromal Tumor Patients
下载PDF
导出
摘要 目的:评价个性化治疗方案应用于胃肠间质瘤患者治疗中的临床治疗效果。方法:本研究的实验样本选自某院收治的胃肠间质瘤患者50例,以2015年1月~2017年3月为样本选取时段,抽签方法进行分组,常规治疗方法的25例患者归为对照组,而实施个性化治疗方案的25例患者归为实验组,治疗之后将两组患者的临床治疗效果进行比照和评价。结果:相比对于对照组患者的治疗总有效率(68.0%),实验组患者的治疗总有效率(92.0%)得以显著提升,实验组症状消除时间(8.01±2.08)d明显缩短,住院天数(10.22±2.35)d明显较短,两组比照数据经统计学软件检验,得出P<0.05的验证结果,统计学具有意义。结论:个性化治疗方案应用于胃肠间质瘤患者治疗中获得了满意的临床治疗效果,可促进治疗效果的提升,在临床治疗中值得大范围应用和推广。 Objective:To evaluate the clinical effect of individualized treatment for gastrointestinal stromal tumor patients.Methods:50 cases of patients with gastrointestinal stromal tumor treated in a hospital from January 2015 to March 2017 were selected and divided into control group(25 cases,routine treatment)and experimental group(25 cases,individualized treatment)according to the drawing of lots.After treatment,the clinical treatment effects of the two groups were compared and evaluated.Results:Compared with the total effective rate of the control group(68.0%),the total effective rate of the experimental group(92.0%)was significantly improved.The symptom elimination time of the experimental group was(8.01±2.08)days,the days of hospitalization was(10.22±2.35)days,which were significantly shorter than those of the control group,and the difference between the two groups was statistically significant(P〈0.05).Conclusion:The individualized treatment has achieved satisfactory clinical effect in the treatment of gastrointestinal stromal tumor patients,which can promote the improvement of the therapeutic effect,and is worth applying and popularizing in the clinical treatment.
作者 林俊快 Lin Junkuai(Huidong County Maternal and Child Health Hospital,Huizhou 51630)
出处 《数理医药学杂志》 2018年第8期1131-1132,共2页 Journal of Mathematical Medicine
关键词 胃肠间质瘤 个性化治疗 临床效果 gastrointestinal stromal tumors individualized treatment clinical effect
  • 相关文献

参考文献7

二级参考文献68

  • 1张信华,何裕隆,马晋平,宋新明,陈创奇,彭建军,詹文华.靶向药物联合外科手术治疗晚期胃肠间质瘤临床分析[J].消化肿瘤杂志(电子版),2010,2(1):25-30. 被引量:3
  • 2沈琳,金懋林.甲磺酸伊马替尼治疗复发或转移性胃肠间质瘤[J].中华肿瘤杂志,2004,26(11):697-699. 被引量:27
  • 3詹文华,王鹏志,邵永孚,伍晓汀,顾晋,李荣,万德森,丁克峰,师英强,于吉人,卢辉山,邹小明,毕建威,孙益红,陆云飞,陈道达,张信华.伊马替尼术后辅助治疗胃肠间质瘤的多中心前瞻性临床试验中期报告[J].中华胃肠外科杂志,2006,9(5):383-387. 被引量:85
  • 4Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant itnatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of radiation therapy oncology group 0132. Ann Surg Oncol, 2011, In press.
  • 5Joensuu H, Eriksson M, Hatrmann J, et al. Twelve vs 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVII1/AIO). ASCO annual meeting, 2011,29 : abstr LBA 1.
  • 6Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 2009,373 (9669) : 1097-1104.
  • 7Corless CL, Ballman KV, Antonesc UC, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST):results of the intergroup phaseIII trial ACOSOC Z9001. J Clin Oncol, 2010,28(15 suppl):abstr 10006.
  • 8Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 2008,39 (10): 1411-1419.
  • 9Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med, 2006,130(10) : 1466-1478.
  • 10Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol, 2008,26(4) :620-625.

共引文献57

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部